IPR & Legal

Novel technology transfer deal reported for antibody candidates

A novel licensing deal among two German universities and the UK Medical Research Council’s commercialization arm is expected to lead to the development of a potential new therapy for rheumatoid arthritis and multiple sclerosis.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany

European Commission proposes a unified patent litigation system

Reform of the patent system in Europe is once more on the political agenda. On 24 March 2009, the European Commission set in motion a procedure that will give it authority to negotiate the creation of a unified patent litigation system for the European Union.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium

Patent dispute between Oxford BioMedica and Bavarian Nordic continues

Bavarian Nordic A/S of Denmark has re-filed a patent infringement suit against Oxford BioMedica Plc in the US District Court for the Southern District of California claiming infringement of Bavarian Nordic’s US patents relating to a viral vector, Oxford BioMedica said.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Denmark

Roundup of recent legal and IP news

Geneart receives European protein patent

Geneart AG has been granted a European patent describing a method for carrying out the selective identification of proteins in vitro. The patent, EP 1913140, underpins the company’s proprietary technology platform relating to the generation and screening of proteins. According to the company, these proteins could become the basis for new therapeutics, vaccines and industrial enzymes. Geneart said its procedure makes it possible to identify optimal variants of a protein from a considerably larger pool more quickly than with conventional methods. This increases the probability of identifying an ideal protein variant such as a strong-binding antibody for a cancer therapy. The European Patent Office granted the patent on 24 December 2008.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Oxford BioMedica says patent suit brought by Bavarian Nordic is dismissed

Oxford BioMedica Plc said that a patent infringement suit brought against it by Bavarian Nordic A/S of Denmark has been dismissed. The suit alleged that the UK company had infringed three of Bavarian Nordic’s US patents for a viral vector used in the Danish company’s smallpox, HIV and cancer programmes.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Appeals body of European Patent Office rejects WARF patent

An appeals body of the European Patent Office has rejected on morality grounds a controversial  stem cell patent application from the Wisconsin Alumni Research Foundation (WARF) relating to a method for obtaining embryonic stem cell cultures from primates.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany

Appeals body of European Patent Office upholds Myriad patent

A decision by the European Patent Office’s (EPO) Opposition Division to revoke a patent for diagnosing susceptibility to breast and ovarian cancer has been overturned by the EPO’s Technical Board of Appeal. However, the scope of the restored patent held by Myriad Genetics Inc has been reduced.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany

Bavarian Nordic sues Oxford BioMedica for alleged patent infringement

The Danish vaccine producer, Bavarian Nordic A/S, has announced a lawsuit against Oxford BioMedica of the UK alleging infringement of three of its US patents for a viral vector used in Bavarian Nordic’s smallpox vaccine.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Denmark

Legal set-back for the US Patent and Trademark Office

A US District Court has permanently enjoined the US Patent and Trademark Office (PTO) from putting into effect new rules that would have limited the number of times an inventor could amend claims in a patent application.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

European Patent Office applies more stringent criteria

The European Patent Office (EPO) has started to apply more stringent criteria to the applications it reviews, including those from the medical sciences.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany

Syndicate content